Drug Resistance in People With Viremia on Dolutegravir-based Antiretroviral Therapy in Sub-Saharan Africa: The DTG RESIST Study.

BORIS DOI
Publisher DOI
PubMed ID
40391923
Description
Dolutegravir resistance is an increasing concern. An analysis of the DTG RESIST study found that among 227 integrase sequences from 7 African countries (all non-B subtypes), 59 (26.0%) had at least 1 major drug resistance mutation (primarily G118R and E138A/K/T), with 49 (21.6%) predicted to have high-level resistance to dolutegravir.
Date of Publication
2025-05-20
Publication Type
article
Subject(s)
600 - Technology::610 - Medicine & health
Keyword(s)
HIV
•
dolutegravir
•
drug resistance
•
sub-Saharan Africa
•
viremia
Language(s)
en
Contributor(s)
Loosli, Tom
Moore, Carolyn Bolton
Buzaalirwa, Lydia
Byakwaga, Helen
Chimbetete, Cleophas
Ebasone, Peter Vanes
Giandhari, Jennifer
Han, Nuri
Huwa, Jacqueline
Kasozi, Charles
Mafoua, Adolphe
Messou, Eugène
Minga, Albert
Muula, Guy
Muyindike, Winnie
Ndala, Arcel Christ Massamba
Semeere, Aggrey
Singh, Lavanya
Kouyos, Roger D
Lessells, Richard
Additional Credits
Institut für Sozial- und Präventivmedizin (ISPM) - HIV, Hepatitis & Tubercolosis
Series
Clinical Infectious Diseases
Publisher
Oxford University Press
ISSN
1537-6591
1058-4838
Related Funding(s)
Access(Rights)
open.access
Show full item